Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

Thrombosis Research

Volumn 108, Issue 1, 2002, Pages 37-42

  Andersen, Kjell ^a   Hurlen, Mette ^b   Arnesen, Harald ^b   Seljeflot, Ingebjørg ^b  

^a Medical Department   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiplatelet therapy; Aspirin non response; Aspirin resistance; P selectin; PFA 100; Secondary prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; PADGEM PROTEIN; THROMBOXANE B2; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE CALCULATION; DRUG RESPONSE; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME;

EID: 0036826025     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00405-X     Document Type: Article

References (19)

1. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
2. Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. Cardiol. 11(3):1995;221-227.
3. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 63:1991;587-593.
4. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm P., Welsh P.A., Brooks L.et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88:2001;230-235.
5. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J.et al. Aspirin response and failure in cerebral infarction. Stroke. 24(3):1993;345-350.
6. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L.et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 25:1994;2331-2336.
7. Hurlen M., Seljeflot I., Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand. Cardiovasc. J. 32:1998;233-237.
8. Blann A.D., Lip G.Y.H. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 128:1997;135-138.
9. Wu K.K. Platelet activation mechanisms and markers in arterial thrombosis. J. Int. Med. 239:1996;17-34.
10. Grotemeyer K.H., Scharafinski H.W., Husstedt I.V. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71:1993;397-403.
11. Buchanan M.R., Schwartz L., Bourassa M., Brister S.J., Peniston C.M. Results of the BRAT study - a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can. J. Cardiol. 16(11):2000 (Nov.);1385-1390.
12. Hurlen M., Abdelnoor M., Smith P., Eriksen J., Arnesen H. Warfarin, aspirin or both after myocardial infarction. N. Engl. J. Med. 347:2002;969-974.
13. De Caterina R., Gianessi D., Bernini W.et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur. Heart J. 6:1985;409-417.
14. Borris M., Söhngen D., Englisch C.et al. Measurement of the effect of aspirin and ticlopidine on platelet function with a simple in vitro bleeding test. Ann. Hematol. 74(Suppl II):1997;73. [Poster].
15. Mammen E.F., Comp P.C., Gosselin R.et al. PFA-100™ system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost. 24:1998;195-202.
16. Kottke-Marchant K., Powers J.B., Brooks L.et al. The effect of antiplatelet drugs, heparin, and pre-analytical variables on platelet function detected by the Platelet Function Analyzer (PFA-100®). Clin. Appl. Thromb./Hemost. 5:1999;122-130.
17. Madan M., Berkowitz S.D., Christie D.J., Jennings L.K., Smit A.C., Sigmon K.N.et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am. Heart J. 141:2001;226-233.
18. Mammen E.F., Alshameeri R.S., Comp P.C. Preliminary data from a field trial of the PFA-100™ system. Semin. Thromb. Hemost. 21(Suppl 2):1995;113.
19. Moons A.H.M., Levi M., Peters R.J.G. Tissue factor and coronary artery disease. Cardiovasc. Res. 53:2002;313-325.